Agendia Test for Molecular Subtyping of Breast Cancer Shown to Better Identify Risk of Disease Recurrence

Test d'Agendia pour Subtyping moléculaire de cancer du sein montré pour identifier mieux le risque de répétition de la maladie

Press releases may be edited for formatting or style | March 11, 2014

Contact:

Liz Dowling (Medical & Consumer Media)
Dowling & Dennis Public Relations

Ensure critical devices are ready to go

Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.

415-388-2794
Liz@DowlingDennis.net

Len Hall (Financial Media)
Allen & Caron Inc. 949-474-4300
len@allencaron.com

Back to HCB News



You Must Be Logged In To Post A Comment Se connecter Se você já criou uma conta, use seu endereço de e-mail e senha para entrar usando o formulário abaixo. Problèmes de connexion: Click here si vous rencontrez des problèmes de connexion. Adresse e-mail: Mot de passe: Mot de passe oublié ? Problèmes de connexion ? Voir notre « Mentions légales » et Notice de Confidentialité Registre L'inscription est gratuite et facile. Aproveite os benefícios dos principais produtos novos e inovadores do mundo. Mercado de equipamentos médicos usados. Inscrivez-vous maintenant !